Previous 10 | Next 10 |
Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cells Cytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be listed on NASDAQ under the ti...
Cellectis S.A. (NASDAQ:CLLS) traded at a new 52-week high today of $38.83. This new high was reached on above average trading volume as 16.4 million shares traded hands, while the average 30-day volume is approximately 313,000 shares. In the past 52 weeks, shares of Cellectis S.A. have t...
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp (TDUP) +7%. Cellectis (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats (SEAT) -6%. Y-mAbs Therapeutic...
Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52 TALEN ® platform UCART20x22 expected to be Cellectis’ first pro...
ALLO-316 was given Fast Track Designation for the treatment of patients with renal cell carcinoma. It is expected that the global kidney cancer market could reach $9.4 billion by 2026. ALLO-647 is a lymphodepletion agent that Allogene has developed to possibly help the expansion a...
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactiva...
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management wil...
French clinical-stage biotechnological company, Cellectis (CLLS +9.0%) is trading higher for the fourth consecutive session on Friday as the market reacts to the Fast Track designation granted by the U.S. Food and Drug Administration (FDA) for its partner Allogene Therapeutics (NASDAQ:ALLO). ...
Gainers: Clearside Biomedical CLSD +38%. Cellectis (NASDAQ:CLLS) +13%. NeuroPace (NASDAQ:NPCE) +12%. 4D pharma LBPS +11%. LifeStance Health (NASDAQ:LFST) +8%. Losers: Orphazyme ORPH -37%. Aesthetic Medical International (NASDAQ:AIH) -19%. Suns...
Cellectis (NASDAQ: CLLS) , a French clinical-stage biopharmaceutical company that specializes in genome engineering technology to fight cancer, saw its shares rise 20.7% this week, according to data provided by S&P Global Market Intelligence . The stock closed at $3.53 on Fr...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...